These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://lawsonewds968128.designertoblog.com/70286744/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide